» Articles » PMID: 19061712

Safety and Efficacy of Consecutive Cycles of Granulocyte-colony Stimulating Factor, and an Intracoronary CD133+ Cell Infusion in Patients with Chronic Refractory Ischemic Heart Disease: the G-CSF in Angina Patients with IHD to Stimulate...

Overview
Journal Am Heart J
Date 2008 Dec 9
PMID 19061712
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Preclinical studies suggest granulocyte-colony stimulating factor (G-CSF) holds promise for treating ischemic heart disease; however; its clinical safety and efficacy in this setting remain unclear. We elected to evaluate the safety and efficacy of G-CSF administration in patients with refractory "no-option" ischemic heart disease.

Methods: Twenty patients (18 males, 2 females, mean age 62.4 years) were enrolled and underwent baseline cardiac ischemia assessment (CA) (angina questionnaire, exercise stress test [EST], technetium Tc 99m sestamibi and dobutamine-stress echocardiographic imaging). Patients then received open-label G-CSF commencing at 10 microg/kg SC for 5 days, with an EST on days 4 and 6 (to facilitate myocardial cytokine generation and stem cell trafficking). After 3 months, CA and the same regimen of G-CSF+ESTs were repeated but, in addition, leukapheresis and a randomized double-blinded intracoronary infusion of CD133+ or unselected cells were performed. Final CA occurred 3 months thereafter.

Results: There were no deaths, but only 16 patients were permitted to complete the study. Eight events fulfilled prespecified "adverse event" criteria, including 4 troponin I-positive events and 2 episodes of thrombocytopenia. Also, frequent minor troponin I-positive events (troponin I<0.9 microg/L) were observed, which did not meet adverse event criteria. The administration of consecutive cycles of G-CSF resulted in stepwise improvements in anginal frequency, EST performance, and Duke treadmill scores (all P<.005). However, from baseline to final follow-up, technetium Tc 99m sestamibi and dobutamine-stress echocardiographic results were unchanged.

Conclusions: Granulocyte-colony stimulating factor administration was associated with improvement in a range of subjective outcomes. However, adverse events were common, and objective measures of cardiac perfusion/ischemia were unchanged.

Citing Articles

Comparing stemness gene expression between stem cell subpopulations from peripheral blood and adipose tissue.

Gonzalez-Garza M, Cruz-Vega D, Cardenas-Lopez A, de la Rosa R, Moreno-Cuevas J Am J Stem Cells. 2018; 7(2):38-47.

PMID: 29938124 PMC: 6013721.


COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial.

Naseri M, Madani H, Ahmadi Tafti S, Moshkani Farahani M, Saleh D, Hosseinnejad H Cell J. 2018; 20(2):267-277.

PMID: 29633605 PMC: 5893299. DOI: 10.22074/cellj.2018.5197.


Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease.

Dorobantu M, Popa-Fotea N, Popa M, Rusu I, Micheu M World J Stem Cells. 2018; 9(12):203-218.

PMID: 29321822 PMC: 5746641. DOI: 10.4252/wjsc.v9.i12.203.


Chasing c-Kit through the heart: Taking a broader view.

Gude N, Sussman M Pharmacol Res. 2017; 127:110-115.

PMID: 28627370 PMC: 5729070. DOI: 10.1016/j.phrs.2017.06.007.


New vessel formation in the context of cardiomyocyte regeneration--the role and importance of an adequate perfusing vasculature.

Michelis K, Boehm M, Kovacic J Stem Cell Res. 2014; 13(3 Pt B):666-82.

PMID: 24841067 PMC: 4213356. DOI: 10.1016/j.scr.2014.04.009.